Covalent Group, Inc. has signed multiple Phase I and Phase II contracts valued at $8.2 million. All of the contracts are with the same client and relate to the development of an agent to treat multiple types of influenza, including Avian Flu. Services include consulting on clinical trial design and protocol development, project and study site management, field operations, data management, and biostatistical support. Kenneth M. Borow, M.D., chief executive officer and president for Covalen...